Sugi Predict

Sugi Predict / Compounds / SCHEMBL14914727

SCHEMBL14914727

SCHEMBL14914727

CC(C)(C)[Si](C)(C)OCc1ccc2cc(N)ccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.46
▸ LMNA P02545 2/20 0.46
▸ POLB P06746 1/20 0.46
▸ CASP6 P55212 1/20 0.46
▸ PLAU P00749 1/20 0.45
▸ HTT P42858 2/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ F2 P00734 1/20 0.37
▸ CHRM2 P08172 1/20 0.37
▸ HTR1A P08908 1/20 0.37
▸ ADRA2A P08913 1/20 0.37
▸ ADORA3 P0DMS8 1/20 0.37
▸ MAOA P21397 1/20 0.37
▸ DRD1 P21728 1/20 0.37
▸ ACHE P22303 1/20 0.37
▸ PTGS1 P23219 1/20 0.37
▸ SLC6A2 P23975 1/20 0.37
▸ SLC6A4 P31645 1/20 0.37
▸ OPRM1 P35372 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13825563 0.84 BACE1 (0.44) BACE1CYSLTR1CYSLTR2GPBAR1
SCHEMBL2223356 0.82 PDE10A (0.33) CYSLTR1CYSLTR2GPBAR1
SCHEMBL12516462 0.78 CYSLTR1 (0.54) CYSLTR1CYSLTR2GPBAR1
SCHEMBL14925244 0.78 PSMB5 (0.33) CYSLTR1CYSLTR2GPBAR1
SCHEMBL18109897 0.78 GPBAR1 (0.49) KDM4EMEN1KMT2ACYSLTR1GPBAR1
SCHEMBL9983520 0.75 BACE1 (0.41) HTTBACE1CYSLTR1CYSLTR2GPBAR1
SCHEMBL16621371 0.74 ALDH1A1 (0.46) KDM4ELMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL7454652 0.74 KDM4E (0.58) KDM4ELMNAPOLBCASP6PLAU
SCHEMBL22689379 0.74 KCNH2 (0.36) KCNH2
SCHEMBL19782657 0.73 BACE1 (0.39) ELANEBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661397-B2 1,4-disubstituted imidazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-05-30 — — US disclosed
US-11661397-B2 1,4-disubstituted imidazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-05-30 — — US disclosed
US-11661397-B2 1,4-disubstituted imidazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-05-30 — — US disclosed
US-11434472-B2 Agent for removing undifferentiated iPS cells Sumitomo Pharma Co., Ltd. (JP) 2022-09-06 — — US disclosed
US-11434472-B2 Agent for removing undifferentiated iPS cells Sumitomo Pharma Co., Ltd. (JP) 2022-09-06 — — US disclosed
US-20210171440-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2021-06-10 — — US disclosed
US-20210171440-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2021-06-10 — — US disclosed
CN-107922386-B 1, 4-disubstituted imidazole derivatives 大日本住友制药株式会社 2021-04-02 — — CN disclosed
US-10807945-B2 1,4-disubstituted imidazole derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-10-20 — — US disclosed
US-10807945-B2 1,4-disubstituted imidazole derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-10-20 — — US disclosed
US-9828362-B2 1,4-disubstituted imidazole derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-11-28 — — US disclosed
US-9828362-B2 1,4-disubstituted imidazole derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-11-28 — — US disclosed
US-20170166552-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2017-06-15 — — US disclosed
US-20170166552-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2017-06-15 — — US disclosed
US-20170166552-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2017-06-15 — — US disclosed
US-8993767-B2 Multiphoton activable quinoline derivatives, their preparation and their uses CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-31 — — US disclosed
US-8993767-B2 Multiphoton activable quinoline derivatives, their preparation and their uses CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-31 — — US disclosed
EP-2523937-B1 Multiphoton activable quinoline derivatives, their preparation and their uses CENTRE NAT RECH SCIENT (FR) 2015-03-11 — — EP disclosed
US-20130116281-A1 Multiphoton Activable Quinoline Derivatives, Their Preparation and Their Uses UNIVERSITÉ PARIS CITÉ (FR) 2013-05-09 — — US disclosed
US-20130116281-A1 Multiphoton Activable Quinoline Derivatives, Their Preparation and Their Uses UNIVERSITÉ PARIS CITÉ (FR) 2013-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166552-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE NR4A3, NR0B1, NR2C2 KDM4E 1942/4885LMNA 3967/4885POLB 3705/4885
US-11434472-B2 Agent for removing undifferentiated iPS cells SALL4, NR4A2, NES KDM4E 304/4885LMNA 2989/4885POLB 3512/4885
US-20210171440-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE NR4A3, NR0B1, NR2C2 KDM4E 1942/4885LMNA 3967/4885POLB 3705/4885
US-11661397-B2 1,4-disubstituted imidazole derivative NR4A3, NR0B1, NR2C2 KDM4E 1942/4885LMNA 3967/4885POLB 3705/4885
US-20130116281-A1 Multiphoton Activable Quinoline Derivatives, Their Preparation and Their Uses NQO2, ACHE, NQO1 KDM4E 2288/4885LMNA 2819/4885POLB 523/4885
US-10807945-B2 1,4-disubstituted imidazole derivative NR0B1, NR4A3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 KDM4E 1821/4885LMNA 4055/4885POLB 3860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.